title: T cell immunophenotypes and DR antigen expression in intravenous drug users. Relationship to human immunodeficiency virus serology.
abstract: Thirty-six intravenous drug users were studied for peripheral blood mononuclear cell (PBMC) immunophenotypes and human immunodeficiency virus (HIV) serological profiles. This population has a high risk for developing HIV infection. Half (18/36) were HIV antibody (Ab) negative (-) and half were positive (+). Total T lymphocytes (CD3+ and CD2+) were not different between HIV Ab-negative and HIV-positive groups. Unactivated T(CD3+DR-) cells/mm3 were less (p = 0.003) in HIV Ab-positive patients (1,467 +/- 628) compared to HIV Ab-negative patients (2,190 +/- 695). T-helper (CD4+) cells/mm3 were also less in HIV Ab-positive patients (762 +/- 344 vs. 1,161 +/- 419, p = 0.005). The most significant difference was in activated T lymphocyte CD3+DR+) percentages where the mean was 9.6% in those HIV Ab-positive compared to 3.8% in seronegatives (p less than 0.001). Preliminary studies showed that in vitro naloxone treatment of PBMC had no effects on immunophenotypic expression except for CD3+DR+ lymphocytes, where a significant reduction was observed in the HIV Ab-positive group (p = 0.022) but not in the HIV ab-negative group. These findings suggest that in certain populations, activated T cells may be an early manifestation of HIV infection.
authors.affiliation: Metropolitan Hospital, New York.
authors.forename: R Y
authors.initials: RY
authors.lastname: Lin
authors.forename: E J
authors.initials: EJ
authors.lastname: Nygren
authors.forename: J E
authors.initials: JE
authors.lastname: Valinsky
authors.forename: H E
authors.initials: HE
authors.lastname: Ralph
mesh_terms: D000328:Adult; D000943:Antigens, Differentiation / Q000032:analysis; D015483:HIV Antibodies / Q000032:analysis*; D016655:HIV Core Protein p24; D006679:HIV Seropositivity / Q000276:immunology; D006684:HLA-DR Antigens / Q000032:analysis*; D006801:Humans; D007275:Injections, Intravenous; D007958:Leukocyte Count / Q000187:drug effects; D009270:Naloxone / Q000494:pharmacology; D009293:Opioid-Related Disorders / Q000276:immunology*; D010641:Phenotype; D012191:Retroviridae Proteins / Q000032:analysis; D013601:T-Lymphocytes / Q000145:classification* / Q000187:drug effects; D006377:T-Lymphocytes, Helper-Inducer / Q000187:drug effects; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects
chemical_list: D000943:Antigens, Differentiation; D015483:HIV Antibodies; D016655:HIV Core Protein p24; D006684:HLA-DR Antigens; D012191:Retroviridae Proteins; D009270:Naloxone